CGON

CG Oncology Inc

Add to Watchlist

Advanced Chart

23.870

-0.98(-3.944%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

24.840

Open

24.530

VWAP

24.34

Vol

293.28K

Mkt Cap

1.89B

Low

23.800

Amount

7.14M

EV/EBITDA(TTM)

Total Shares

76.25M

1.23B

EV/OCF(TTM)

P/S(TTM)

3.25K

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

124.20K

-72.76%

128.83K

+199.6%

108.71K

-2.06%

Estimates Revision

The market is revising Downward the revenue expectations for CG Oncology, Inc. (CGON) for FY2025, with the revenue forecasts being adjusted by -85.4% over the past three months. During the same period, the stock price has changed by -5.13%.

Revenue Estimates for FY2025

Revise Downward

-85.4%

In Past 3 Month

Stock Price

Go Down

-5.13%

In Past 3 Month

9 Analyst Rating

135.19% Upside

Wall Street analysts forecast CGON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGON is 56.14 USD with a low forecast of 23.00 USD and a high forecast of 82.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

1 Hold

0 Sell

Strong Buy

135.19% Upside

Current: 23.870

Low

23.00

Averages

56.14

High

82.00

135.19% Upside

Current: 23.870

Low

23.00

Averages

56.14

High

82.00

BofA

Buy

downgrade

$63 -> $62

2025-08-10

New

Reason

BofA

Price Target

$63 -> $62

2025-08-10

New

downgrade

Buy

Reason

BofA lowered the firm's price target on CG Oncology to $62 from $63 and keeps a Buy rating on the shares post the Q2 report. The firm sees significant value generation opportunities for CG over the next 12-18. The company remains a frontrunner in the HR non-muscle invasive bladder cancer space, the analyst tells investors in a research note.

RBC Capital

Outperform

downgrade

$68 -> $53

2025-07-16

Reason

RBC Capital

Price Target

$68 -> $53

2025-07-16

downgrade

Outperform

Reason

RBC Capital lowered the firm's price target on CG Oncology to $53 from $68 and keeps an Outperform rating on the shares. The firm is refreshing its views on the stock following key opinion leader discussions on Creto, additional diligence, and a meeting with the management, the analyst tells investors in a research note. RBC sees a favorable setup into the second half of the year, with topline readouts in HR NMIBC and BCG-naive patients likely to clear the bar and drive as much as 20% potential upside, the firm added.

Goldman Sachs

NULL -> Buy

initiated

$40

2025-07-10

Reason

Goldman Sachs

Price Target

$40

2025-07-10

initiated

NULL -> Buy

Reason

Goldman Sachs resumed coverage of CG Oncology with a Buy rating and $40 price target. The firm believes the clinical profile of cretostimogene is competitive with TAR-200.

Morgan Stanley

Overweight

maintain

$52 -> $56

2025-06-18

Reason

Morgan Stanley

Price Target

$52 -> $56

2025-06-18

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on CG Oncology to $56 from $52 and keeps an Overweight rating on the shares. Even with recent and anticipated approvals in the non-muscle invasive bladder cancer space, the firm believes the bladder cancer landscape is large enough for multiple players and it views cretostimogene as having "best-in-disease potential" and meaningfully differentiated by its durability and safety data, the analyst tells investors.

HC Wainwright & Co.

Andres Maldonado

Strong Buy

Reiterates

$75

2025-03-31

Reason

HC Wainwright & Co.

Andres Maldonado

Price Target

$75

2025-03-31

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Andres Maldonado

Strong Buy

Reiterates

$75

2025-03-25

Reason

HC Wainwright & Co.

Andres Maldonado

Price Target

$75

2025-03-25

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for CG Oncology Inc (CGON.O) is -10.36, compared to its 5-year average forward P/E of -18.77. For a more detailed relative valuation and DCF analysis to assess CG Oncology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-18.77

Current PE

-10.36

Overvalued PE

-13.83

Undervalued PE

-23.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-14.72

Current EV/EBITDA

-7.01

Overvalued EV/EBITDA

-7.82

Undervalued EV/EBITDA

-21.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Overvalued

5Y Average PS

3536.85

Current PS

7486.95

Overvalued PS

5058.01

Undervalued PS

2015.69

Financials

Annual

Quarterly

FY2025Q2

YoY :

-100.00%

0.00

Total Revenue

FY2025Q2

YoY :

+88.53%

-48.74M

Operating Profit

FY2025Q2

YoY :

-100.00%

N/A

Net Income after Tax

FY2025Q2

YoY :

+92.86%

-0.54

EPS - Diluted

FY2025Q2

YoY :

+73.38%

-27.97M

Free Cash Flow

FY2025Q2

YoY :

-100.00%

N/A

Gross Profit Margin - %

FY2025Q2

YoY :

+60.67%

-17.07K

FCF Margin - %

FY2025Q2

YoY :

+756.90%

-145.92K

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 100% over the last month.

Sold

0-3

Months

56.0K

USD

3-6

Months

86.8K

USD

6-9

Months

19.7M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

25.0K

Volume

6-9

Months

1.6M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

92.0K

Volume

Months

6-9

1.2M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 100% over the last month.

Sold

0-3

Months

56.0K

USD

3-6

Months

86.8K

USD

6-9

Months

19.7M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

CGON News & Events

Events Timeline

2025-08-08 (ET)

2025-08-08

08:03:09

CG Oncology reports Q2 EPS (54c), consensus (44c)

2025-07-29 (ET)

2025-07-29

16:42:14

CG Oncology announces Delaware Superior Court ruling in its favor

2025-05-13 (ET)

2025-05-13

08:04:02

CG Oncology reports Q1 EPS (45c), consensus (37c)

News

4.0

07-16Benzinga

Beyond The Numbers: 7 Analysts Discuss CG Oncology Stock

3.5

07-07Newsfilter

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

8.0

06-20NASDAQ.COM

Noteworthy Friday Option Activity: IGT, CGON, GME

People Also Watch

PTGX

Protagonist Therapeutics Inc

Apogee Therapeutics Inc

FAQ

What is CG Oncology Inc (CGON) stock price today?

The current price of CGON is 23.87 USD — it has decreased -3.94 % in the last trading day.

CGON

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

CGON News & Events

Events Timeline

News

People Also Watch

FAQ

What is CG Oncology Inc (CGON) stock price today?

What is CG Oncology Inc (CGON)'s business?

What is the price predicton of CGON Stock?

What is CG Oncology Inc (CGON)'s revenue for the last quarter?

What is CG Oncology Inc (CGON)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for CG Oncology Inc (CGON)'s fundamentals?

How many employees does CG Oncology Inc (CGON). have?

What is CG Oncology Inc (CGON) market cap?